“…The results from this study from Resolvyx Pharmaceuticals, for which CNS was the original scientific founder, were the first demonstration of clinical efficacy with pro-resolving agents in humans (Business Wire, 2009; de Paiva et al, 2012). The Phase II trial controlling inflammation in the eye with topical drops (Business Wire, 2009) was based on the physiologic roles (Gronert, 2010; Li et al, 2010; Erdinest et al, 2014) of SPM such as resolvins and lipoxins in the eye (Li et al, 2013; Hodges et al, 2016; Dartt et al, 2011; Cortina and Bazan, 2011) and apparent gender differences, where females display delayed wound healing of cornea tissue and reduced 15-LOX-derived SPM such as lipoxin A 4 (Gao et al, 2015; Wang et al, 2012). Since 15- R/S -methyl lipoxin A 4 , an analog of the aspirin-triggered form of lipoxin A 4 , one of the first stop signals and pro-resolving mediators, is effective in infantile eczema in a double-blind, placebo-controlled study randomized at two different centers (Wu et al, 2013), and LXA 4 , resolvin D1, RvD2 and maresin 1 act on T-cell responses (Chiurchiu et al, 2016; Gao et al, 2015), it is likely that SPM have physiologic roles in human skin and barrier functions that remain to be studied, and their functions extend from the resolution phase into the adaptive immune response (Ramon et al, 2012).…”